MarginsXMarginsX
Home › Markets › Health Care › OCGN

Ocugen Inc. (OCGN)

OCGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7730
-6.62% on the day
Market cap
$262.3M
Micro cap
Revenue · 2025
$4.4M
+8.8% on 2024
Net income · 2025
-$67.8M
-1537.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1372299/000162828026014435/0001628280-26-014435-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerOCGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2014
SEC CIK0001372299
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$4.4M
Net income-$67.8M
Operating income-$62.9M
Net margin-1537.4%
Operating margin-1425.7%
Revenue growth+8.8%
Cash$18.6M
Total assets$43.5M
P/E (computed)Net income was not positive
P/S (computed)59.4×

Warning signs

Cash runway
4.6 months
$24.6M cash at September 30, 2026
Share count, 1 year
+8.6%
2025-10-31 to 2026-10-30 · +32.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 4, 2026
Insider net buying, 12 months
-$563K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"After evaluating these conditions and management's plans, the Company has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued."
10-Q 2026-11-04
Cash and burn$24.6M cash; operating cash flow -$15.9M a quarter.Report 2026-09-30
Shares outstanding339,306,603 (2026-10-30); 312,320,112 a year earlier; 256,502,434 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-01-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $26K, sold $589K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.0M-$3.6M-$15.7M$24.6M$1.8M$4.8M10-Q 2026-11-04
Q2 2026
2026-06-30
$1.5M-$24.9M-$12.2M$100.1M$1.7M$4.6M10-Q 2026-08-06
Q1 2026
2026-03-31
$1.5M-$19.2M-$21.8M$31.9M$29.2M$4.5M10-Q 2026-05-08
Q4 2025
2025-12-31
-$193K-$17.7M-$14.0M$18.6M$28.8M$4.4M10-K 2026-03-04
Q3 2025
2025-09-30
$1.8M-$20.1M-$12.9M$32.9M$28.4M$5.4M10-Q 2026-11-04
Q2 2025
2025-06-30
$1.4M-$14.7M-$10.7M$27.0M$28.0M$4.8M10-Q 2026-08-06
Q1 2025
2025-03-31
$1.5M-$15.3M-$19.4M$37.8M$27.7M$4.5M10-Q 2026-05-08
Q4 2024
2024-12-31
$764K-$13.9M-$10.4M$58.8M$28.7M$4.1M10-K 2026-03-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-01-21
Latest annual report10-K2026-03-04
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-10
Latest proxyDEFA14A2026-11-06

Source: SEC EDGAR submissions feed, 895 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.5%
1 month-6.4%
3 months-38.7%
Year to date-38.7%
1 year-33.2%
From 52-week high-66.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LXEOLexeo Therapeutics Inc.$3.23+12.54%$265.0M
PLXProtalix BioTherapeutics Inc. (DE)$3.03-0.66%$255.5M
SABSSAB Biotherapeutics Inc.$3.00+1.35%$270.3M
DTILPrecision BioSciences Inc.$7.28-3.77%$277.6M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M
AGENAgenus Inc.$6.29-6.54%$284.6M
CABACabaletta Bio Inc.$1.11-13.28%$239.4M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier